Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAAS and Antidiuretic Function with SGLT2i in T2D
NCT03917758Unknown
- Sponsor
- University of Turin
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of canagliflozin, dapagliflozin and empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by University of Turin. Primary endpoints: Brain Natriuretic Peptide at 90 days, Vasopressin at 90 days and 5 more. Status: unknown.
02
Drugs
canagliflozindapagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03917758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917758.